Its finest hour may have come in 1962 when a stubborn physician/pharmacologist, Frances Oldham Kelsey, insisted on seeing better safety data for a drug used widely in Europe to treat "morning sickness" before she would allow it to be approved in the U.S. When the tragedy of thalidomide became known, the FDA was lauded for its cautious reasoning. 4 During the 1980s' AIDS epidemic, the FDA was vilified by activists who initially misunderstood its function. 5 It is not the job of the FDA to develop and test new drugs, or to set their prices, but to evaluate the data presented to it by drug manufacturers and cautiously recommend approval or no approval. The Prescription Drug User Funding Act (PDUFA) of 1992 started shifting the manner in which the FDA was funded. Requiring commercial entities to pay for their own oversight agency sounds like an odd way to do business, but it is not uncommon in the U.S. where agencies such as Customs and Immigration Services (CIS) and the Federal Communication Commission (FCC) also pay for their own oversight. 6 The FDA is an imperfect watchdog. Its bite is not quite toothless, but it does little damage. Eli Lilly's olanzapine (Zyprexa®) has been implicated in hundreds of deaths and thousands of cases of metabolic syndrome; fines were paid, but no one went to jail. 7 Purdue Pharmaceuticals used fabricated data to get its long-acting oxycodone (OxyContin®) approved, and thousands of people became addicted and died; fines were paid, but no one served jail time.
8 Rofecoxib (Vioxx®) was approved because Wyeth withheld data from the FDA showing that its drug quadrupled the risk of myocardial infarction; a fine was paid, but no one served jail time. 9 Can we anticipate any major change? It is unlikely as long as the pharmaceutical industry controls the purse strings -not only of the FDA but of the government. There are more than two pharmaceutical lobbyists for every representative in Washington, D.C. 10 The recent price rise in lifesaving drugs like epinephrine and naloxone show how powerless the government is in preventing patient harm.
The article in this month's WestJEM by Zuabi et al. is based on a talk that I developed about 10 years ago but was seldom asked to give. When I gave it at the American Academy of Emergency Medicine Scientific Assembly in 2016, WestJEM Editor-in-Chief Mark Langdorf was in the audience and became intrigued. I was unable to dedicate the time to write the article but sent all of my references and resources, and this article was what came out of it. They did a great job of synthesizing my talk into a fascinating article, far better than I could have. I congratulate the authors.
